Treatment of hereditary angioedema in the pediatric patient

Shana Kalaria, Timothy Craig

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hereditary angioedema (HAE) is an autosomal dominant disease, with the expectation that there is a risk of 50%, if a parent has HAE, of inheriting the disease. Manifestations of the disease start early in life for some patients, but symptoms frequently increase during the transition from childhood to adolescence. Unfortunately, most medications are not approved for use in children. This requires off-label use for most of the medications that are U.S. Food and Drug Administration approved for HAE. For this reason, we have sought to identify the use of medications approved and unapproved and used off label for children with HAE.

Original languageEnglish (US)
Pages (from-to)171-175
Number of pages5
JournalPediatric, Allergy, Immunology, and Pulmonology
Volume27
Issue number4
DOIs
StatePublished - Dec 1 2014

Fingerprint

Hereditary Angioedemas
Pediatrics
Off-Label Use
United States Food and Drug Administration
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

@article{5760ef7ad86a4ba094012b116d298e8e,
title = "Treatment of hereditary angioedema in the pediatric patient",
abstract = "Hereditary angioedema (HAE) is an autosomal dominant disease, with the expectation that there is a risk of 50{\%}, if a parent has HAE, of inheriting the disease. Manifestations of the disease start early in life for some patients, but symptoms frequently increase during the transition from childhood to adolescence. Unfortunately, most medications are not approved for use in children. This requires off-label use for most of the medications that are U.S. Food and Drug Administration approved for HAE. For this reason, we have sought to identify the use of medications approved and unapproved and used off label for children with HAE.",
author = "Shana Kalaria and Timothy Craig",
year = "2014",
month = "12",
day = "1",
doi = "10.1089/ped.2014.0422",
language = "English (US)",
volume = "27",
pages = "171--175",
journal = "Pediatric, Allergy, Immunology, and Pulmonology",
issn = "2151-321X",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

Treatment of hereditary angioedema in the pediatric patient. / Kalaria, Shana; Craig, Timothy.

In: Pediatric, Allergy, Immunology, and Pulmonology, Vol. 27, No. 4, 01.12.2014, p. 171-175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of hereditary angioedema in the pediatric patient

AU - Kalaria, Shana

AU - Craig, Timothy

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Hereditary angioedema (HAE) is an autosomal dominant disease, with the expectation that there is a risk of 50%, if a parent has HAE, of inheriting the disease. Manifestations of the disease start early in life for some patients, but symptoms frequently increase during the transition from childhood to adolescence. Unfortunately, most medications are not approved for use in children. This requires off-label use for most of the medications that are U.S. Food and Drug Administration approved for HAE. For this reason, we have sought to identify the use of medications approved and unapproved and used off label for children with HAE.

AB - Hereditary angioedema (HAE) is an autosomal dominant disease, with the expectation that there is a risk of 50%, if a parent has HAE, of inheriting the disease. Manifestations of the disease start early in life for some patients, but symptoms frequently increase during the transition from childhood to adolescence. Unfortunately, most medications are not approved for use in children. This requires off-label use for most of the medications that are U.S. Food and Drug Administration approved for HAE. For this reason, we have sought to identify the use of medications approved and unapproved and used off label for children with HAE.

UR - http://www.scopus.com/inward/record.url?scp=84934753996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934753996&partnerID=8YFLogxK

U2 - 10.1089/ped.2014.0422

DO - 10.1089/ped.2014.0422

M3 - Article

AN - SCOPUS:84934753996

VL - 27

SP - 171

EP - 175

JO - Pediatric, Allergy, Immunology, and Pulmonology

JF - Pediatric, Allergy, Immunology, and Pulmonology

SN - 2151-321X

IS - 4

ER -